Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a price target of $7.
September 16, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Mereo BioPharma Group, maintaining a $7 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $7 price target by Cantor Fitzgerald suggests positive sentiment and confidence in Mereo BioPharma's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100